262 related articles for article (PubMed ID: 29343972)
1. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
Castelli G; Pelosi E; Testa U
Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
4. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
6. Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia.
Dhall A; Zee BM; Yan F; Blanco MA
Front Oncol; 2019; 9():432. PubMed ID: 31192132
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.
Lu R; Wang GG
Front Oncol; 2017; 7():241. PubMed ID: 29075615
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
[TBL] [Abstract][Full Text] [Related]
9. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
10. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
11. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
12. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
13. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
14. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
Abdel-Wahab O; Levine RL
Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
[TBL] [Abstract][Full Text] [Related]
15. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
Bullinger L; Döhner K; Döhner H
J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
[TBL] [Abstract][Full Text] [Related]
16. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
17. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
18. Somatic alterations and dysregulation of epigenetic modifiers in cancers.
Aumann S; Abdel-Wahab O
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):24-34. PubMed ID: 25111821
[TBL] [Abstract][Full Text] [Related]
19. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
20. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
Fathi AT; Abdel-Wahab O
Adv Hematol; 2012; 2012():469592. PubMed ID: 21811504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]